ALT-801
- Generic Name
- ALT-801
- Drug Type
- Biotech
- CAS Number
- 1188450-53-4
- Unique Ingredient Identifier
- QWZ40O5W6K
- Background
ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).
Altimmune Halts Nasal COVID-19 Vaccine Development After Poor Phase 1 Results
• Altimmune's intranasal COVID-19 vaccine AdCOVID showed insufficient immune response in Phase 1 trials, leading to the termination of the development program.
• The company's nasal vaccine aimed to provide room-temperature stability and enhanced mucosal immunity, but failed to generate adequate antibody levels against SARS-CoV-2.
• Following this setback, Altimmune will redirect its focus to ALT-801, its peptide drug candidate for NASH and obesity treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath